Section 21-2C-06 – Acceptance of Gratuities Prohibited
Members and alternate members of the Board, Board staff, and third–party contractors may not accept any gift or donation of services or property that indicates a potential conflict of interest or has the appearance of biasing the work of the Board.
Section 21-2C-07 – Study and Report — Pharmaceutical Distribution and Payment System in State; Policy Options Used in Other States and Countries
On or before December 31, 2021, the Board, in consultation with the Stakeholder Council, shall: (1) Study: (i) The entire pharmaceutical distribution and payment system in the State; and (ii) Policy options being used in other states and countries to lower the list price of pharmaceuticals, including: 1. Setting upper payment limits; 2. Using a reverse auction marketplace; and 3. Implementing […]
Section 21-2C-08 – Collection, Review, and Use of Transparency Data for Prescription Drug Products
(a) On or before December 31, 2021, the Board shall: (1) Collect and review publicly available information regarding prescription drug product manufacturers, health insurance carriers, health maintenance organizations, managed care organizations, wholesale distributors, and pharmacy benefits managers; and (2) (i) Identify states that require reporting on the cost of prescription drug products; and (ii) Initiate a process of entering into […]
Section 21-2C-09 – Cost Review of Prescription Drug Products With Affordability Challenges
(a) (1) After identifying prescription drug products as required by § 21–2C–08 of this subtitle, the Board shall determine whether to conduct a cost review as described in subsection (b) of this section for each identified prescription drug product by: (i) Seeking Stakeholder Council input about the prescription drug product; and (ii) Considering the average cost share of the […]
Section 21-2C-10 – Confidentiality
(a) All information and data obtained by the Board under this subtitle, that is not otherwise publicly available: (1) Is considered to be a trade secret and confidential and proprietary information; and (2) Is not subject to disclosure under the Public Information Act. (b) Only Board members and staff may access trade secrets and confidential and proprietary data and […]
Section 21-2C-11 – Funding Source
(a) In this section, “Fund” means the Prescription Drug Affordability Fund. (b) (1) The Board shall assess and collect an annual fee on: (i) Manufacturers that sell or offer for sale prescription drug products to persons in the State; (ii) Pharmacy benefits managers, as defined in § 15–1601 of the Insurance Article; (iii) Carriers, as defined in § 19–132 of this […]